Evaluation of CD43 expression in non-hematopoietic malignancies

Area of Science:

• Oncology
• Immunohistochemistry
• Cancer Biomarkers

Background:

• CD43 is a leukocyte surface marker and a key diagnostic tool for hematologic malignancies.
• Aberrant CD43 expression in non-hematopoietic tumors is inconsistently reported in existing literature.
• Clarifying CD43 expression patterns in non-hematopoietic neoplasms is crucial for accurate diagnosis.

Purpose of the Study:

• To evaluate CD43 expression in a large cohort of non-hematopoietic neoplasms using immunohistochemistry.
• To determine the diagnostic utility of CD43 in differentiating hematopoietic from non-hematopoietic malignancies.
• To investigate the patterns of aberrant CD43 expression in various non-hematopoietic tumor types.

Main Methods:

• Immunohistochemistry (IHC) staining for CD43 (clone DF-T1) was performed on 307 non-hematopoietic neoplasms.
• Tissue microarrays and individual case sections were analyzed.
• Proportion of positive cells, stain localization (nuclear, cytoplasmic, membranous), and intensity were recorded.

Main Results:

• 32% (98/307) of non-hematopoietic neoplasms showed focal, weak nuclear CD43 positivity.
• Positive cases included pancreatic, breast, thyroid, and lung adenocarcinomas, among others.
• No cases exhibited strong, membranous CD43 staining typical of hematopoietic neoplasms.

Conclusions:

• Most non-hematopoietic neoplasms are negative for CD43.
• Focal, weak nuclear CD43 positivity can occur in a subset of non-hematopoietic tumors.
• Uniform, strong membranous CD43 expression remains specific for hematopoietic neoplasms.